Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based Biogen Idec, which is engaged in the development, manufacturing and commercialization of therapies, has appointed Robert Hamm as its new COO. Mr Hamm replaces Hans Hasler, who is leaving the company.
Subscribe to our email newsletter
Mr Hamm has been executive vice president of pharmaceutical operations and technology at the company since 2007. As COO, Mr Hamm will add global business operations to his responsibilities.
Mr Hamm joined Biogen Idec in 1994. He served as senior vice president of neurology strategic business unit beginning from 2004 to 2007.
Jim Mullen, CEO of Biogen Idec, said: “Bob has vast experience in virtually all aspects of our operations. His strong commercial understanding and outstanding leadership qualities make him an excellent choice to be our COO. I want to thank Hans Peter for his many years of service at Biogen Idec during a period of tremendous growth and international expansion. We wish him well.”